Billiontoone (NASDAQ:BLLN) Price Target Raised to $125.00 at JPMorgan Chase & Co.

Key Points

• JPMorgan raised BillionToOne's price target to $125 (from $120) and kept an "overweight" rating, implying roughly a 37.6% upside from the current price.
• BillionToOne posted a quarterly surprise with $0.34 EPS vs. $0.01 expected and revenue of $108.4M (up 83.8% YoY), driving the stock up about 11.6% to $90.83 on heavy volume.
• Analysts are generally positive but mixed — the consensus is a "Moderate Buy" with an average target of $122.43 (6 Buys, 3 Holds, 1 Sell).

Billiontoone (NASDAQ:BLLN - Get Free Report) had its target price raised by JPMorgan Chase & Co. from $120.00 to $125.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 37.63% from the company's current price.

Several other analysts have also weighed in on BLLN. Wall Street Zen raised shares of Billiontoone from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Billiontoone in a report on Friday, May 1st. BTIG Research dropped their price objective on shares of Billiontoone from $140.00 to $130.00 and set a "buy" rating for the company in a report on Thursday. Wells Fargo & Company dropped their price objective on shares of Billiontoone from $110.00 to $90.00 and set an "equal weight" rating for the company in a report on Thursday, March 5th. Finally, Guggenheim dropped their price objective on shares of Billiontoone from $120.00 to $100.00 and set a "buy" rating for the company in a report on Monday, March 30th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Billiontoone presently has a consensus rating of "Moderate Buy" and an average target price of $122.43.

Billiontoone Trading Up 11.6%

NASDAQ BLLN traded up $9.43 on Thursday, reaching $90.83. The company's stock had a trading volume of 926,306 shares, compared to its average volume of 338,266. Billiontoone has a 52 week low of $61.96 and a 52 week high of $138.70. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.32 and a current ratio of 11.69. The company's 50-day moving average price is $77.51. The stock has a market capitalization of $4.18 billion and a price-to-earnings ratio of 427.67.

Billiontoone (NASDAQ:BLLN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. During the same quarter last year, the company earned ($0.39) earnings per share. The business's revenue was up 83.8% on a year-over-year basis. Analysts anticipate that Billiontoone will post 0.42 earnings per share for the current fiscal year.

Institutional Trading of Billiontoone

Hedge funds have recently modified their holdings of the stock. Rossby Financial LCC bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $25,000. Wells Fargo & Company MN bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $76,000. Smartleaf Asset Management LLC bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Billiontoone during the fourth quarter valued at approximately $82,000. Finally, Renaissance Capital LLC bought a new position in Billiontoone in the fourth quarter valued at approximately $201,000.

About Billiontoone

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.